Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Cash from Financing Activities (2019 - 2025)

Avidity Biosciences' Cash from Financing Activities history spans 7 years, with the latest figure at -$5.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 137.06% year-over-year to -$5.1 million; the TTM value through Dec 2025 reached $851.0 million, down 28.63%, while the annual FY2025 figure was $851.0 million, 28.63% down from the prior year.
  • Cash from Financing Activities reached -$5.1 million in Q4 2025 per RNA's latest filing, down from $850.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $850.4 million in Q3 2025 to a low of -$5.1 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $133.0 million, with a median of $28.0 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 856060.0% in 2024, then plummeted 137.06% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $20.7 million in 2021, then soared by 1076.28% to $243.7 million in 2022, then tumbled by 86.91% to $31.9 million in 2023, then plummeted by 56.97% to $13.7 million in 2024, then tumbled by 137.06% to -$5.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Cash from Financing Activities are -$5.1 million (Q4 2025), $850.4 million (Q3 2025), and $3.8 million (Q2 2025).